|
Dec 21 |
PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based C...
Versamune® T-cell activating platform... |
|
Dec 09 |
PDS Biotechnology Appoints Seth Van Voorhees as Chief Financial Officer...
FLORHAM PARK, N.J., Dec. 09, 2020 (GLOBE... |
|
Nov 16 |
PDS Biotech Announces New and Broad Versamune® Platform Patent Claims...
Granted methods patent for Versamune® platform by the... |
|
Nov 12 |
PDS Biotech to Present at the Virtual Fall Investor Summit on November 16th-18th....
(Accesswire — 11/12/20) - PDS Biotechnology... |
|
Nov 11 |
PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update...
FLORHAM PARK, N.J., Nov. 11, 2020 (GLOBE... |
|
Nov 10 |
PDS Biotech and Farmacore Announce Updates to Co-Development of Versamune®-Based COVID-19 Vaccine...
PDS0203 prioritized for clinical development by... |
|
Nov 09 |
PDS Biotech Initiates VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent/Metastatic Head and Nec...
VERSATILE-002 Trial for First Line Treatment of... |
|
Nov 05 |
PDS Biotechnology Appoints Renowned Oncologist Otis Brawley, M.D. to its Board of Directors...
FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE... |
|
Oct 29 |
PDS Biotechnology Announces Feature in “Grand Rounds” Webinar hosted by Alliance Global Partners and Conference Call...
PDS Biotech to participate in “Grand Rounds: a... |
|
Oct 26 |
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in A...
PDS Biotech progresses second Phase 2 human... |
|
Oct 01 |
PDS Biotechnology Announces Participation in Noble Capital Markets Virtual Road Show Series...
FLORHAM PARK, N.J., Oct. 01, 2020 (GLOBE... |
|
Sep 28 |
PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients wit...
FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE... |
|
Sep 08 |
PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences...
FLORHAM PARK, N.J., Sept. 08, 2020 (GLOBE... |
|
Aug 31 |
PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series...
FLORHAM PARK, N.J., Aug. 31, 2020 (GLOBE... |
|
Aug 13 |
PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter'...
FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE... |
|
Aug 13 |
PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update...
FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE... |
|
Aug 11 |
PDS Biotechnology Corporation Announces Pricing of $16.5 Million Public Offering of Common Stock...
FLORHAM PARK, N.J., Aug. 11, 2020 (GLOBE... |
|
Aug 10 |
PDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock...
FLORHAM PARK, N.J., Aug. 10, 2020 (GLOBE... |
|
Jul 30 |
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results...
FLORHAM PARK, N.J., July 30, 2020 (GLOBE... |
|
Jul 27 |
PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19...
Versamune-CoV-2 (PDS0203) generated high levels of... |
|
Jul 14 |
PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine...
PDS Biotech ramps up third infectious disease... |
|
Jun 22 |
PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the ...
NCI-led Phase 2 clinical trial of this reported... |
|
Jun 17 |
PDS Biotechnology and Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine...
Brazilian government to provide initial funding... |
|
Jun 15 |
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute...
FLORHAM PARK, N.J., June 15, 2020 (GLOBE... |
|
Jun 04 |
PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy i...
FLORHAM PARK, N.J., June 04, 2020 (GLOBE... |
|
Jun 02 |
PDS Biotechnology to Present at the 2020 Virtual Investor Summit...
FLORHAM PARK, N.J., June 02, 2020 (GLOBE... |
|
May 13 |
PDS Biotechnology Announces Publication at American Society of Clinical Oncology (ASCO) 2020...
FLORHAM PARK, N.J., May 13, 2020 (GLOBE... |
|
May 13 |
PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update...
FLORHAM PARK, N.J., May 13, 2020 (GLOBE... |
|
May 04 |
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2020 Financial Results...
FLORHAM PARK, N.J., May 04, 2020 (GLOBE... |
|
Apr 29 |
PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Produ...
NCI to study PDS0103, in addition to planned... |
|
Apr 16 |
PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VE...
Expanded infectious disease program to address... |
|
Apr 09 |
PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors...
PRINCETON, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- PDS... |
|
Mar 27 |
PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update...
PRINCETON, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- PDS... |
|
Mar 23 |
PDS Biotechnology Announces Resignation of Andrew Saik as CFO...
PRINCETON, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- PDS... |
|
Mar 05 |
PDS Biotechnology Expands Patent Portfolio for its Novel Versamune® Platform...
Granted Composition of Matter Patent for... |
|
Feb 27 |
PDS Biotechnology Announces Commencement of Work Under a Pre-Clinical Collaboration with Farmacore Biotechnology for Tub...
PRINCETON, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- PDS... |
|
Feb 24 |
PDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors...
PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- PDS... |
|
Feb 17 |
PDS Biotechnology to Present at Noble Capital Markets' 16th Annual Small & Microcap Investor Conference...
Princeton, NJ, February 10, 2020 - PDS... |
|
Feb 14 |
PDS Biotechnology Corporation Announces Closing of Public Offering...
PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- PDS... |
|
Feb 11 |
PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stoc...
PRINCETON, N.J., Feb. 11, 2020 (GLOBE NEWSWIRE) -- PDS... |
|
Feb 05 |
PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference...
PRINCETON, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- PDS... |
